

A detailed 3D visualization of a cell-based target identification platform. The central focus is a large, textured, orange-red mass representing a cell or tissue structure. Several smaller, blue, spherical particles with white speckles are scattered around and embedded within this mass, representing target identification or drug delivery. The background is a dark teal gradient with a curved orange and yellow swoosh at the top right.

Cell-Based Target Identification

Integrated Oncology Platform to advance preclinical development

Our integrated Oncology Platform is uniquely positioned to identify lead compounds, advance validated candidates, and expedite transition to *in vivo* efficacy studies.

Well-Characterized Cell Line Menu

We have more than 600 STR-verified, mycoplasma free cell lines that can be used in both comprehensive screens or targeted assessments of your lead compounds. Many are matched to *in vivo* models for ease of translation to the later stages of development.

OmniScreen Cost-Effective, Large-Scale Cell Screening

High throughput screening of at least 50 cell lines per run to maximize your savings. Includes a positive drug control, and all cell line revival costs are covered by CrownBio. Choose from the **OmniPanel**, **XenoSelect**, **PrimePanel**, and **RNASeqPanels**.

OmniPanel

Over 500 cell lines covering multiple cancer types routinely run for various projects

XenoSelect

Over 200 cell lines validated and matched with xenograft mouse models to move seamlessly from *in vitro* to *in vivo* studies

RNASeqPanel

More than 170 genomically characterized cell lines to correlate mutation status, copy number variation, and expression levels with drug response

The Power to Choose

Our menu is expansive and constantly growing, so we focus on making it easy for you to select the models that have the characteristics important in your study, e.g. sequencing data, gene expression data, response to SoC, etc.

Database	Description	Get Access
OncoExpress™	Oncology models	oncoexpress.crownbio.com
HuBase™	PDX derived models and cell lines	hubase.crownbio.com
MuBase™	Immuno-oncology models	mubase.crownbio.com
XenoBase™	Cell lines/cell line derived xenograft	xenobase.crownbio.com

Improved Translation with Matched *In Vitro*, *In Vivo*, and *Ex Vivo* Models

Crown Bioscience's Integrated Oncology Portfolio contains a range of *in vitro* linked models and assays to support a swift and seamless transition to *ex vivo* and *in vivo* studies.

Comprehensive Analysis Services


Common Applications Include:

- High throughput cytotoxicity screening
- *In vitro* drug combination studies
- 3D clonogenic assays
- 3D Tumor Growth Assay
- Target validation studies
- Adhesion, migration, and invasion assays
- Angiogenesis assays
- Apoptosis studies

- ADCC and CDC analyses
- Cell cycle analysis
- Pharmacodynamics/ pharmacokinetics analysis

Available Methodologies Include:

- FACS
- Western blot
- Whole exome sequencing
- RNA sequencing
- Si/sh RNA knockdown
- Multiplexed immunoassays



Get in touch



Sales

US: +1 858 622 2900
UK: +44 870 166 6234

busdev@crownbio.com
www.crownbio.com



Science

consultation@crownbio.com

